-
Why Viking Therapeutics Shares Are Finding Renewed Buying Interest
Tuesday, November 13, 2018 - 11:45am | 494Read More...Viking Therapeutics Inc (NASDAQ: VKTX) shares — which cooled off following an 87-percent jump Sept. 18 in reaction to positive top-line results from the mid-stage trial of VK2809 — were experiencing the return of upward momentum Tuesday. The stock was up 1.79 percent at $11....
-
Viking Therapeutics Gains 5% As Company Highlights Positive Data From A Phase 1b Clinical Trial
Monday, April 11, 2016 - 10:41am | 312Read More...Shares of Viking Therapeutics Inc (NASDAQ: VKTX), a clinical stage biopharmaceutical company that focuses on the treatment of metabolic and endocrine disorders, gained more than 5 percent on Monday. Viking Therapeutics highlighted positive data from a phase 1b clinical trial of VK2809 in...
